Cargando…

Clinical Impact of Revised Cefepime Breakpoint in Patients With Enterobacteriaceae Bacteremia

The impact of the revised Clinical and Laboratory Standards Institute interpretative criteria for cefepime in Enterobacteriaceae remains unclear. We applied the new breakpoint on 644 previously defined cefepime-susceptible Enterobacteriaceae isolates. We found no differences in mortality or microbio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foong, Kap Sum, Carlson, Abigail L, Munigala, Satish, Burnham, Carey-Ann D, Warren, David K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735685/ https://www.ncbi.nlm.nih.gov/pubmed/31660387 http://dx.doi.org/10.1093/ofid/ofz341

Ejemplares similares

Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
por: Wang, Ruibin, et al.
Publicado: (2016)

292. Impact of the BACT/ALERT VIRTUO blood culture system in the management of Staphylococcus aureus bacteremia
por: Chavez, Miguel A, et al.
Publicado: (2020)

Blood culture utilization practices among febrile and/or hypothermic inpatients
por: Foong, Kap Sum, et al.
Publicado: (2022)

Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae Producing AmpC β-Lactamase
por: Park, Ki-Ho, et al.
Publicado: (2017)

Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by Enterobacteriaceae
por: Park, Ga Eun, et al.
Publicado: (2021)

650. Clinical Performance Evaluation of Virtuo Blood Culture System in a Tertiary Care Hospital
por: Chavez, Miguel A, et al.
Publicado: (2020)

Clinical Impact of Noninvasive Plasma Microbial Cell-Free Deoxyribonucleic Acid Sequencing for the Diagnosis and Management of Pneumocystis jirovecii Pneumonia: A Single-Center Retrospective Study
por: Foong, Kap Sum, et al.
Publicado: (2022)

In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae
por: Crandon, Jared L., et al.
Publicado: (2015)

1599. Clinical Outcomes for Patients Treated with Fluoroquinolones for Bacteremia Caused by Enterobacteriaceae Reclassified as Not Susceptible by Updated CLSI Breakpoints
por: Fleischner, Zachary, et al.
Publicado: (2020)

1549. Impact of New Fluoroquinolone Breakpoints on Enterobacteriaceae Susceptibility Rates and Clinical Outcomes
por: Pettit, Natasha N, et al.
Publicado: (2019)

191. Appropriateness of Empiric Antibiotics for Enterobacteriaceae Bacteremia
por: Smith, Brandon J, et al.
Publicado: (2019)

Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan
por: Lee, Ching-Chi, et al.
Publicado: (2019)

Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study
por: Su, Ting-Yi, et al.
Publicado: (2017)

Impact of revised breakpoints on the categorization of susceptibility of Enterobacterales to temocillin
por: Farfour, Eric, et al.
Publicado: (2023)

Clinical Impact of Expedited Pathogen Identification and Susceptibility Testing for Gram-negative Bacteremia and Candidemia Using the Accelerate Pheno™ System
por: Burnham, Jason, et al.
Publicado: (2017)

Clinical Usefulness of the 2010 Clinical and Laboratory Standards Institute Revised Breakpoints for Cephalosporin Use in the Treatment of Bacteremia Caused by Escherichia coli or Klebsiella spp.
por: Ku, Nam Su, et al.
Publicado: (2015)

1446. The Impact of Enterobacteriaceae Isolate Breakpoints on Prescriber Treatment Choices for Discordant Pattern Urinary Tract Infections
por: Lee, Philip, et al.
Publicado: (2019)

2240. Breaking Dogmas: A Single Center Evaluation of Empiric Vancomycin Use Among Intensive Care Unit Patients with Suspected Pneumonia, Bacteremia or Sepsis
por: Xie, Christina Y, et al.
Publicado: (2023)

Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems
por: Walker, Kristy J., et al.
Publicado: (2018)

P081: Cefepime-tazobactam: a new antibiotic against ESBL producing enterobacteriaceae in cancer patients
por: Biswas, S, et al.
Publicado: (2013)

Cefepime: Cefepime-induced encephalopathy: case report
Publicado: (2022)

Cefepime-Resistant Pseudomonas aeruginosa
por: Akhabue, Ehimare, et al.
Publicado: (2011)

183. Impact of Revised Piperacillin/Tazobactam Clinical Breakpoints on Enterobacterales Isolates Identified in Blood Cultures
por: Moore, Nicholas M, et al.
Publicado: (2022)

Beta-Lactam Probability of Target Attainment Success: Cefepime as a Case Study
por: Selig, Daniel J., et al.
Publicado: (2023)

Mortality Impact of CLSI Carbapenem Breakpoint Changes in Enterobacteriaceae Bloodstream Infections: a Patient-level Analysis of Published Data
por: O’Donnell, J Nicholas, et al.
Publicado: (2017)

Analytical Performance Characteristics of the Accelerate Pheno™ System for Pathogen Identification and Susceptibility Testing for Gram-negative Bacteremia and Candidemia
por: Burnham, Jason, et al.
Publicado: (2017)

Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia
por: Lee, Yi-Tzu, et al.
Publicado: (2016)

Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam
por: Yang, Xianggui, et al.
Publicado: (2019)

Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis: a comparison with bacteremia caused by Enterobacteriaceae
por: Bang, Ji Hwan, et al.
Publicado: (2013)

Diabetes does not affect outcome in patients with Enterobacteriaceae bacteremia
por: Peralta, Galo, et al.
Publicado: (2009)

Comparison of efficiency of intravitreal ceftazidime and intravitreal cefepime in the treatment of experimental Pseudomonas aeruginosa endophthalmitis
por: Deniz, Nurettin, et al.
Publicado: (2013)

1360. Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global Collection of Enterobacteriaceae Including Resistant Phenotypes
por: Hackel, Meredith, et al.
Publicado: (2018)

2416. Risk Factors and Outcomes of Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae Compared With Carbapenem Susceptible Enterobacteriaceae
por: Mahmood, Syed Faisal
Publicado: (2018)

Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
por: Fukuchi, Takahiko, et al.
Publicado: (2016)

959 Epidemiology and Treatment of Enterobacteriaceae Bacteremia: Combination vs Monotherapy
por: Berkowitz, Nina, et al.
Publicado: (2014)

Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia
por: Lee, Chen-Hsiang, et al.
Publicado: (2018)

Increased 30-Day Mortality Associated With Carbapenem-Resistant Enterobacteriaceae in Children
por: Chiotos, Kathleen, et al.
Publicado: (2018)

KPC and NDM-1 Genes in Related Enterobacteriaceae Strains and Plasmids from Pakistan and the United States
por: Pesesky, Mitchell W., et al.
Publicado: (2015)

Cryptococcal Infection of the Ventriculoperitoneal Shunt in an Immunocompetent Patient
por: Foong, Kap Sum, et al.
Publicado: (2016)

Correlation of Minimum Inhibitory Concentration Breakpoints and Methicillin Resistance Gene Carriage in Clinical Isolates of Staphylococcus epidermidis
por: Eftekhar, Fereshteh, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_bab4ckgl3ea3ec174jgjvo5d3q